Carlos Quezada-Ruiz

Jan 13, 2025 | healio.com | Alex Young |Christine Klimanskis |Carlos Quezada-Ruiz

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients who received 4D-150 3E10 vg/eye experienced an 8.4 letter increase in BCVA. 4DMT is progressing to a phase 3 trial for 4D-150 3E10 vg/eye.

Jul 11, 2024 | healio.com | Carlos Quezada-Ruiz |Anthony DeFino |David Mullin |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS,of Genentech/Roche shares an update on Susvimo and the port delivery platform.